 BOSTON, March 19, 2021 GLOBE NEWSWIRE -- X4 Pharmaceuticals, Inc. Nasdaq: XFOR, a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has agreed to sell an aggregate of 6,321,837 shares of its common stock, including pre-funded warrants to purchase common stock, to certain institutional accredited investors in a private investment in public equity PIPE financing. X4 anticipates that gross proceeds from the PIPE will be approximately 55.0 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company, based on the offering price of 8.70 per share or 8.69 per pre-funded warrant, the last reported sale price of X4s common stock on The Nasdaq Global Market on March 18, 2021. 